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SUMMARY
Investigations of noninvasive prenatal screening for aneuploidy by analysis of circulating cell-free 
DNA (cfDNA) have shown high sensitivity and specificity in both high-risk and low-risk cohorts. 
However, the overall low incidence of aneuploidy limits the positive predictive value of these 
tests. Currently, the causes of false positive results are poorly understood. We investigated four 
pregnancies with discordant prenatal test results and found in two cases that maternal duplications 
on chromosome 18 were the likely cause of the discordant results. Modeling based on population-
level copy-number variation supports the possibility that some false positive results of noninvasive 
prenatal screening may be attributable to large maternal copy-number variants. (Funded by the 
National Institutes of Health and others.)
Methods of noninvasive prenatal screening1 have advanced rapidly in clinical practice, with 
aneuploidy screening based on analysis of circulating cfDNA now routinely offered to 
women with high-risk pregnancies. Owing to the high reported accuracy of these screening 
tests,2,3 attention has shifted to low-risk cohorts, in which the reduced incidence of 
aneuploidy may limit the positive predictive value of noninvasive prenatal screening.4 A 
recent prospective analysis of cfDNA-based noninvasive prenatal screening in 1914 low-risk 
pregnancies showed false positive rates of 0.3%, 0.2%, and 0.1% for trisomies 21, 18, and 
13, respectively — rates that were lower than those observed with standard screening tests.5 
However, the positive predictive value was 45.5% for trisomy 21 and 40.0% for trisomy 
18,5 highlighting the need for follow-up diagnostic testing. Norton et al.6 now report in the 
Journal higher positive predictive values with cfDNA-based noninvasive prenatal screening 
that uses a different method, albeit with a higher “no call” rate; “no call” results are 
ambiguous and could mask a clinically important finding.
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The mechanisms underlying false positive results of cfDNA-based noninvasive prenatal 
screening remain incompletely elucidated.7 Explanatory hypotheses include maternal 
mosaicism,8,9 undetected tumors,10 the vanishing twin syndrome,11 and confined placental 
mosaicism,12,13 as well as technical errors. Although case reports have documented 
examples of underlying causes of false positive and other aberrant results, only a small 
proportion have been comprehensively explained.8
Methods of cfDNA-based noninvasive prenatal screening include massively multiplex 
polymerase-chain-reaction (PCR) assay,14 shotgun sequencing,15,16 and targeted 
sequencing.17 The Illumina Verifi and Sequenom MaterniT21 PLUS tests are based on 
counting statistics that naturally arise from shotgun sequencing of total cfDNA in maternal 
plasma. After isolation, sequencing, and alignment of cfDNA fragments, a minority of 
which are fetoplacentally derived (mean, 13%, but with considerable variation during 
pregnancy and between pregnancies18), the reads are sorted into bins. Each bin contains 
reads that have been unambiguously derived from a specific chromosome, and the 
distributions for each chromosome are converted to standard normal distributions. The 
binned counts for the newly analyzed cfDNA sample are compared with reference 
distributions, yielding per-chromosome z scores that estimate the likelihood of fetal 
aneuploidies. In diploid pregnancies, false positive detection of trisomy may occur owing to 
type I errors — that is, the infrequent and chance sampling of z scores above 4.0. In 
statistical terms, the probability that the random variable Z will have a value greater than 4.0 
is expressed as Pr(Z>4.0), which equals approximately 3 in 100,000.
This approach implicitly assumes that every woman carries the same proportion of genetic 
material on a given chromosome. In fact, chromosomes vary slightly in composition and 
size from person to person owing to inherited or de novo copy-number variants, in which a 
genomic region is deleted or duplicated. For example, a maternal duplication effectively 
increases the length of the chromosome on which it resides, thereby increasing the 
proportion of cfDNA derived from that chromosome. In such a person, sequencing of 
cfDNA would yield overrepresentation of reads derived from the chromosome containing 
the copy-number variant relative to that chromosome in reference persons, potentially 
leading to false interpretation of the results as indicating fetal trisomy (Fig. 1A).
The capacity of a maternal copy-number variant to alter the interpretation of noninvasive 
prenatal screening is augmented by the fact that the vast majority of cfDNA is maternally 
derived. In a diploid pregnancy in which the mother carries a duplication, the increased 
number of reads derived from the additional copy of the duplicated region shifts the 
sampling distribution for this pregnancy to the right relative to the underlying reference 
distribution (Fig. 1B). The probability of a false positive statistical test would then exceed 
Pr(Z>4.0), with the extent of excess driven primarily by the size of the duplication.
We sought to investigate whether maternal copy-number variants could give rise to false 
positive results of noninvasive prenatal screening. As a proof of principle, we enrolled four 
pregnant women who had discordant findings: positive cfDNA-based screening results with 
normal clinical outcomes. Subsequently, we modeled the potential population-level effects 
of maternal copy-number variants on false positive results.
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PATIENTS AND SAMPLE PROCESSING
Participants were identified from a population of consecutive patients with false positive 
results on noninvasive prenatal screening who were referred for perinatal genetic counseling 
at the University of Washington. After delivery, normal clinical outcomes were confirmed; 
all the participants had fetal diploidy on the basis of antenatal genetic amniocentesis, normal 
newborn examinations, or both.
For each pregnancy, maternal peripheral-blood samples were obtained at the time of 
enrollment, and cord-blood samples were obtained at delivery. Plasma was purified, and 
cfDNA was isolated, sequenced, and aligned to the reference genome with the use of 
standard methods (see the Methods section in the Supplementary Appendix, available with 
the full text of this article at NEJM.org). Maternal peripheral-blood mononuclear cells 
(PBMCs) were obtained concurrently, and DNA was isolated from these cells for validation 
of copy-number variants.
IDENTIFICATION OF COPY-NUMBER VARIANTS
Reads from maternal cfDNA unambiguously derived from each chromosome were tallied 
and examined for overrepresentation of portions of chromosome 13, 18, or 21. Candidate 
copy-number variants greater than 250 kb in size were identified by visual inspection of 
read-depth profiles and confirmed by means of PCR assay and Sanger sequencing of 
maternal PBMC DNA and cord-blood DNA (see the Methods section in the Supplementary 
Appendix).
MODELING
For a range of sizes of maternal copy-number variants, we calculated the factor increase in 
the probability of a false positive statistical test for each chromosome, on the basis of the 
properties of the Z distribution underlying the test (see the Methods section in the 
Supplementary Appendix). Per-chromosome coefficients of variation were used to estimate 
the standard deviation of the number of reads derived from each chromosome in presumed 
diploid reference cohorts (Table S1 in the Supplementary Appendix). The mean numbers of 
additional reads expected to be derived from the duplicated regions were converted to 
chromosome-specific standard-deviation units, which were then used to calculate adjusted 
probabilities of false positive results. Next, we estimated the population frequencies of 
nonpathogenic copy-number variants on chromosomes 13, 18, and 21. To obtain this 
estimate, we evaluated a reference panel of copy-number variants of 19,584 persons, 
predominantly of European descent (Table S2 in the Supplementary Appendix), to 
determine duplications on relevant chromosomes with at least 50% overlap with unique 
genomic regions.
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We enrolled four participants, each with discordant results of noninvasive prenatal screening 
and clinical findings. In each case, noninvasive prenatal screening was performed by means 
of Illumina Verifi. Three participants had a positive screening result for trisomy 18, and the 
other participant had a positive screening result for trisomy 13 (complete clinical 
information is provided in Table S3 in the Supplementary Appendix). In two of the three 
participants with a positive screening result for trisomy 18, we identified maternal copy-
number variants on chromosome 18 (Fig. 1C).
Patient 1 was a 36-year-old primigravida. Noninvasive prenatal screening at 18 weeks of 
gestation indicated fetal trisomy 18. Ultrasonographic findings at 20 weeks of gestation were 
consistent with normal fetal anatomy and concordant biometry. Diagnostic testing by means 
of genetic amniocentesis was consistent with a diploid male pregnancy. The remainder of 
the pregnancy was uncomplicated, and a healthy male infant was delivered at term.
Patient 3 was a 34-year-old multigravida. The results of noninvasive prenatal screening at 12 
weeks of gestation were consistent with fetal trisomy 18. At 12, 16, and 20 weeks of 
gestation, fetal ultrasonography showed normal anatomy and concordant biometry. Genetic 
amniocentesis was declined. The remainder of the pregnancy was uncomplicated, and a 
healthy female infant was delivered at term.
ANALYSIS OF CFDNA
Analysis of cfDNA from Patient 1 identified a duplicated region on chromosome 18 
containing portions of 18p11.31 and 18p11.23 (1.15 Mb). Analysis of cfDNA from Patient 3 
identified a duplication on chromosome 18 covering a region of 18p11.31 (487 kb) (Fig. 
1C). For both patients, maternal DNA from PBMCs was used to validate the copy-number 
variant by means of PCR assay and Sanger sequencing (Table S4 and Fig. S1, S2, and S3 in 
the Supplementary Appendix).
MODELING
To model the effect of these duplications on the risk of false positive results of noninvasive 
prenatal screening, we calculated the theoretical factor increase in the probability of false 
positive results for a range of sizes of copy-number variants on chromosomes 13, 18, and 21 
(Fig. 2, and Fig. S4 in the Supplementary Appendix). The calculated increase depends on 
several factors, including the total number of reads per sample, the coefficient of variation 
for the chromosome in question,19 the fetal fraction, and fetal inheritance of the maternal 
copy-number variant (Table S5 in the Supplementary Appendix). As the fetal fraction 
increases, the signal of overrepresentation is dampened if the copy-number variant is not 
transmitted to the fetus, and increasingly large duplications are necessary to reach the same 
factor increase in the probability of a false positive result. Conversely, if the copy-number 
variant is transmitted to the fetus, the maternally inherited chromosome also contributes to 
the signal of overrepresentation, obviating dependency on the fetal fraction. We estimate 
that the copy-number variant that was present in Patient 1, duplicating 1.15 Mb and 
Snyder et al. Page 4













inherited by the fetus, increased the probability of a false positive statistical test on 
chromosome 18 by a factor of approximately 15,650, such that in the absence of fetal 
aneuploidy, the test was nearly equivalent to flipping a coin. The 487-kb copy-number 
variant that was present in Patient 3 but not inherited by the fetus had a more modest 
estimated effect, yielding an increase in the probability of false positive results by a factor of 
128 to 262 for plausible fetal fractions of 5 to 20%.
FACTORS CONTRIBUTING TO EFFECTS OF MATERNAL COPY-NUMBER VARIANTS
We identified two population factors that contribute to the effects of maternal copy-number 
variants. First, the distribution of copy-number-variant sizes varies according to 
chromosome length, with chromosomes 13 and 18 having higher population frequencies of 
large duplications than the smaller chromosome 21 (Fig. 2). Chromosomes with higher 
population burdens of copy-number variants — particularly the largest such variants — 
should be more susceptible to false positive results. Second, the coefficient of variation of 
sequence reads for each chromosome modulates the effect of the size of copy-number 
variants on the probability of false positive results. For example, chromosome 13, which has 
the highest of the three examined coefficients of variation, is the most buffered from the 
effects of copy-number variants (Fig. 2).
DISCUSSION
Recent advances in cfDNA-based noninvasive prenatal screening have yielded screening 
techniques with substantially better test-performance characteristics than previous 
approaches.5,6 However, the positive predictive value remains limited in both high-risk and 
low-risk populations, and improvement of these screening tests, including delineation of 
potential mechanisms of false positive results, will be essential as uptake of this form of 
screening continues to accelerate. We identified and validated large maternal copy-number 
variants on chromosome 18 as plausible causes of discordant results in two of four 
pregnancies with false positive results of noninvasive prenatal screening. Furthermore, using 
frequencies of copy-number variants from a largely European cohort, we estimated that 
maternal copy-number variants may contribute substantially to an elevated risk of false 
positive results.
Our study has several limitations. First, the study samples were not obtained at the same 
time as the initial samples that were sent for commercial testing; therefore, it is possible that 
underlying biologic changes occurring during gestation were masked. Although the presence 
of maternal copy-number variants is unaffected by the timing of sample collection, the effect 
of these copy-number variants on statistical inference of fetal ploidy does depend on fetal 
inheritance and the fetal fraction, the latter of which increases with gestational age. Thus, 
later in gestation, marginally larger copy-number variants are generally required to achieve 
the same factor increase in the probability of a false positive result when the copy-number 
variant is not transmitted (Fig. 2, and Table S5 in the Supplementary Appendix). Second, we 
did not directly observe any large copy-number variants underlying false positive results of 
noninvasive prenatal screening on chromosome 13 or 21. Third, our preliminary estimates of 
the effect of maternal copy-number variants from modeling based on population-wide 
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frequencies are only as good as the assumptions and data that went into them, which include 
the methods themselves (which are not necessarily the best possible or static), the 
coefficients of variation for each chromosome, the set of unique genomic regions that 
potentially harbor copy-number variants (Fig. S4 in the Supplementary Appendix), and the 
joint distribution of sizes of copy-number variants and allele frequencies. For example, the 
spectrums of sizes and frequencies of copy-number variants may differ between European 
and non-European populations, underscoring the importance of future studies with diverse 
patient groups.
A small cohort such as ours is insufficient to determine the precise effects of maternal copy-
number variants on aggregate false positive rates of cfDNA-based noninvasive prenatal 
screening. Other cfDNA-based screening methods, such as the targeted analysis of cfDNA 
from selected genomic regions,6 may be more or less susceptible to false positive results 
attributable to maternal copy-number variants. However, even as larger studies are 
warranted, implementations of noninvasive prenatal screening based on counting statistics 
arising from shotgun sequencing may be immediately modifiable to reduce the number of 
false positive results attributable to maternal copy-number variants. For example, when a 
maternal copy-number variant is identified (in cfDNA or PBMC-derived DNA, with the 
latter unconfounded by the fetus), reads derived from the affected region could be discarded 
or proportionally discounted, or the effective size of the chromosome could be adjusted. 
Alternatively, z scores could be calculated in fixed genome bin sizes, rather than for whole 
chromosomes, such that region-specific outliers that potentially correspond to maternal 
copy-number variants could be flagged or discarded; this approach is analogous to methods 
developed by Srinivasan et al.20
Our study has several potential implications for the spectrum of causes of discordant 
prenatal test results. First, although the incidence of fetal aneuploidy increases with maternal 
age, the risk of a false positive result of noninvasive prenatal screening that is caused by a 
maternal copy-number variant would not depend on maternal age, with affected women at 
risk for recurrent false positive results in subsequent pregnancies. Second, the presence of 
maternal copy-number losses or deletions of sequence could potentially induce the opposite 
effect — that is, false negative results of noninvasive prenatal screening in truly aneuploid 
pregnancies, although this issue has not been directly addressed in this study (Fig. 1A). 
Although the effect of the size of copy-number variants on hypothetical false negative 
results cannot be quantified without coefficients of variation based on truly aneuploid 
pregnancies, the co-occurrence of trisomic pregnancy and statistically relevant deletions is 
expected to be very infrequent.
In conclusion, although prospective studies have shown excellent performance of cfDNA-
based noninvasive prenatal screening, the positive predictive value remains limited, and 
follow-up diagnostic testing remains essential. The effects of false positive screening results 
go beyond the clinical risks and financial costs of diagnostic testing and include potentially 
substantial psychological stress for patients. Our modeling, which is based on population-
wide frequencies of copy-number variants, provides initial estimates on which larger, more 
definitive studies can be based. Though cfDNA-based noninvasive prenatal screening is 
currently focused clinically on high-risk populations,21 it will probably be increasingly used 
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as a primary screening test over time. Throughout this transition, continued investigation 
and refinement of methodologic approaches to improve the performance of noninvasive 
prenatal screening will be critical.
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Figure 1. The Role of Maternal Copy-Number Variants (CNVs) in False Positive Results of 
DNA-based Noninvasive Prenatal Screening
Panel A is a schematic representation of cell-free DNA (cfDNA) analysis. The cfDNA in 
maternal plasma contains primarily maternal cfDNA and a smaller proportion of fetal 
cfDNA. The threshold for triggering a positive cfDNA test is indicated by the vertical 
dashed line. The combination of fetal diploidy and the absence of a maternal CNV results in 
a true negative test. The combination of fetal trisomy and the absence of a maternal CNV 
results in a true positive test. The combination of fetal diploidy and the presence of a 
maternal CNV that duplicates a portion of a relevant chromosome results in a false positive 
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test. Hypothetically, the combination of fetal trisomy on a specific chromosome and the 
presence of a maternal CNV that deletes a portion of the same chromosome could result in a 
false negative test. Panel B is a schematic representation of the effect of a maternal CNV on 
the probability of a false positive test result, expressed as Pr(Z>4.0), which equals 
approximately 3 in 100,000. Maternal duplications shift the sampling distribution of the test 
to the right, and the underlying reference distribution is unchanged. In Panel C, copy-
number profiles based on normalized cfDNA read depth are consistent with duplicated 
regions on chromosome 18 in two of the four patients. Profiles of Patients 2 and 4 are 
consistent with two copies throughout the region of interest. Patients 1 and 3 have an 
increased copy number in contiguous regions, suggestive of duplications.
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Figure 2. Population Frequency and Estimated Effect of Maternal CNVs on False Positive Test 
Rates
The burden of nonpathogenic copy-number increases on chromosomes 13 (Panel A), 18 
(Panel B), and 21 (Panel C) in a cohort of 19,584 persons, predominantly of European 
ancestry, is shown for a range of CNV sizes (blue circles, right vertical axis). CNV 
frequencies in each size bin refer to CNVs of the given size or larger. For each size bin, the 
estimated factor increase in the probability of a false positive test resulting from the copy-
number increase is shown for a range of fetal fractions (gray and colored lines, left vertical 
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axis). The sizes of the CNVs present on chromosome 18 in Patients 1 and 3 are highlighted 
(dashed vertical lines).
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